Coherus Oncology Inc

CHRS remains in a Stage 4 decline with a confirmed LH/LL regime and price below downward-sloping EMAs, supporting a medium-term bearish bias. The recent bounce into the 9/21EMA zone lacks follow-through, making immediate selling unfavorable. We defer execution, trimming into rallies at EMAs and prior resistance areas rather than chasing current extension.

• ↑Q2 2026 revenue $13.6M (+37% YoY; +15% QoQ) driven by Lactorsi.
• ↑Cash $105.3M after cutting R&D to $21.4M and SG&A to $21M.
• ↓Net loss narrowed to $33.3M (-$0.22/share) remains significant.